Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
Tweet Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $111.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
